Document Detail

Management of trastuzumab-related cardiac dysfunction.
MedLine Citation:
PMID:  20728700     Owner:  NLM     Status:  MEDLINE    
Trastuzumab is the standard of care for the treatment of patients with ERB2-positive breast cancer. In a minority of patients, trastuzumab is associated with an increased incidence of cardiac dysfunction that ranges from asymptomatic decreases in left ventricular ejection fraction to symptomatic heart failure. In trials in the adjuvant setting, the difference in the incidence of cardiac events between the control and trastuzumab-containing arms was less than 4%. The baseline evaluation and oncologic setting (adjuvant versus metastatic disease) drive algorithms for the cardiac monitoring and management of these patients. When a patient develops documented left ventricular dysfunction, standard treatments for the management of heart failure should be prescribed. Trastuzumab cardiac dysfunction is an important clinical entity that can be managed effectively and individualized to maximize the cancer treatment benefit and minimize the risk and consequences of cardiac dysfunction.
Joseph R Carver
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Progress in cardiovascular diseases     Volume:  53     ISSN:  1873-1740     ISO Abbreviation:  Prog Cardiovasc Dis     Publication Date:    2010 Sep-Oct
Date Detail:
Created Date:  2010-08-23     Completed Date:  2010-09-27     Revised Date:  2013-05-08    
Medline Journal Info:
Nlm Unique ID:  0376442     Medline TA:  Prog Cardiovasc Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  130-9     Citation Subset:  AIM; IM    
Copyright Information:
Copyright 2010 Elsevier Inc. All rights reserved.
Abramson Cancer Center of The University of Pennsylvania, 1600 Penn Tower, Philadelphia, PA 19104, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / adverse effects*
Breast Neoplasms / drug therapy*,  pathology
Heart Failure / chemically induced,  diagnosis,  physiopathology,  therapy*
Risk Assessment
Ventricular Dysfunction, Left / chemically induced,  diagnosis,  physiopathology,  therapy*
Ventricular Function, Left / drug effects
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antineoplastic Agents; P188ANX8CK/trastuzumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Role of biomarkers in chemotherapy-induced cardiotoxicity.
Next Document:  Reversibility of left ventricular dysfunction resulting from chemotherapy: can this be expected?